[go: up one dir, main page]

FR2935001B1 - Emulsion fluorescente - Google Patents

Emulsion fluorescente

Info

Publication number
FR2935001B1
FR2935001B1 FR0804601A FR0804601A FR2935001B1 FR 2935001 B1 FR2935001 B1 FR 2935001B1 FR 0804601 A FR0804601 A FR 0804601A FR 0804601 A FR0804601 A FR 0804601A FR 2935001 B1 FR2935001 B1 FR 2935001B1
Authority
FR
France
Prior art keywords
oil phase
lambda
droplets
label
fluorescent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0804601A
Other languages
English (en)
Other versions
FR2935001A1 (fr
Inventor
Laurent Guyon
Mathieu Goutayer
Y Garcia Fabrice Navarro
Nogues Isabelle Texier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Commissariat a lEnergie Atomique et aux Energies Alternatives CEA
Original Assignee
Commissariat a lEnergie Atomique CEA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR0804601A priority Critical patent/FR2935001B1/fr
Application filed by Commissariat a lEnergie Atomique CEA filed Critical Commissariat a lEnergie Atomique CEA
Priority to PCT/IB2009/006766 priority patent/WO2010018460A1/fr
Priority to CA2733994A priority patent/CA2733994A1/fr
Priority to EP09786223A priority patent/EP2331144A1/fr
Priority to JP2011522565A priority patent/JP2011530577A/ja
Priority to CN200980139595.6A priority patent/CN102170913A/zh
Priority to US13/058,984 priority patent/US20110195029A1/en
Publication of FR2935001A1 publication Critical patent/FR2935001A1/fr
Application granted granted Critical
Publication of FR2935001B1 publication Critical patent/FR2935001B1/fr
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
    • A61K49/0069—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
    • A61K49/0076—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form dispersion, suspension, e.g. particles in a liquid, colloid, emulsion
    • A61K49/0078—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form dispersion, suspension, e.g. particles in a liquid, colloid, emulsion microemulsion, nanoemulsion
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A61K49/0034—Indocyanine green, i.e. ICG, cardiogreen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/533—Production of labelled immunochemicals with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Dispersion Chemistry (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Inorganic Chemistry (AREA)
  • Nanotechnology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
FR0804601A 2008-08-14 2008-08-14 Emulsion fluorescente Expired - Fee Related FR2935001B1 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
FR0804601A FR2935001B1 (fr) 2008-08-14 2008-08-14 Emulsion fluorescente
CA2733994A CA2733994A1 (fr) 2008-08-14 2009-08-11 Emulsion fluorescente
EP09786223A EP2331144A1 (fr) 2008-08-14 2009-08-11 Émulsion fluorescente
JP2011522565A JP2011530577A (ja) 2008-08-14 2009-08-11 蛍光エマルジョン
PCT/IB2009/006766 WO2010018460A1 (fr) 2008-08-14 2009-08-11 Émulsion fluorescente
CN200980139595.6A CN102170913A (zh) 2008-08-14 2009-08-11 荧光乳液
US13/058,984 US20110195029A1 (en) 2008-08-14 2009-08-11 Fluorescent emulsion

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0804601A FR2935001B1 (fr) 2008-08-14 2008-08-14 Emulsion fluorescente

Publications (2)

Publication Number Publication Date
FR2935001A1 FR2935001A1 (fr) 2010-02-19
FR2935001B1 true FR2935001B1 (fr) 2011-12-30

Family

ID=40220167

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0804601A Expired - Fee Related FR2935001B1 (fr) 2008-08-14 2008-08-14 Emulsion fluorescente

Country Status (7)

Country Link
US (1) US20110195029A1 (fr)
EP (1) EP2331144A1 (fr)
JP (1) JP2011530577A (fr)
CN (1) CN102170913A (fr)
CA (1) CA2733994A1 (fr)
FR (1) FR2935001B1 (fr)
WO (1) WO2010018460A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2934954B1 (fr) 2008-08-14 2011-07-22 Commissariat Energie Atomique Emulsion fluorescente de vert d'indocyanine
FR2934955B1 (fr) 2008-08-14 2011-07-08 Commissariat Energie Atomique Encapsulation d'agents therapeutiques lipophiles ou amphiphiles dans des nanoemulsions
FR2934953B1 (fr) 2008-08-14 2011-01-21 Commissariat Energie Atomique Nanoemulsions de nanocristaux
US20140356293A1 (en) * 2012-01-20 2014-12-04 The Research Foundation of the State of University of New York Fluorescent compositions with enhanced fluorescence and methods based thereon
FR2991196B1 (fr) 2012-05-29 2014-06-27 Capsum Nanoparticules ciblantes pour une application biologique
CN104152138A (zh) * 2014-06-26 2014-11-19 苏州科技学院 一种弱光频率上转换o/w型微乳液体系
CN109187450B (zh) * 2018-08-01 2020-10-27 傅英 一种基于量子点的生物分子浓度检测方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4906100A (en) * 1988-05-13 1990-03-06 University Of Cincinnati Method of detecting adriamycin (doxorubicin) or daunomycin in the environment
GB2251381B (en) * 1990-07-19 1995-01-25 Charwell Pharma Emulsified fluorescein diester diagnostic compositions
US6540981B2 (en) * 1997-12-04 2003-04-01 Amersham Health As Light imaging contrast agents
ES2213899T3 (es) * 1997-04-29 2004-09-01 Amersham Health As Agentes de contraste utilizados en tecnicas de formacion de imagen en base a la luz.
US6123923A (en) * 1997-12-18 2000-09-26 Imarx Pharmaceutical Corp. Optoacoustic contrast agents and methods for their use
AR018376A1 (es) * 1998-05-26 2001-11-14 Novartis Ag Composiciones farmaceuticas que se pueden dispersar de una manera espontanea y el uso de las mismas para la manufactura de un medicamento
DE19852245A1 (de) * 1998-11-12 2000-05-18 Asat Ag Applied Science & Tech 5-Aminolävulinsäure-Nanoemulsion
CA2534426A1 (fr) * 2003-08-08 2005-02-17 Barnes-Jewish Hospital Particules d'emulsion destinees a l'imagerie et a la therapie et procedes d'utilisation de celles-ci
EP1563851A1 (fr) * 2004-02-17 2005-08-17 Yissum Research Development Company of the Hebrew University of Jerusalem Emulsions cationiques ciblées avec des anticorps pour la livraison de drogues
US20050255044A1 (en) * 2004-05-14 2005-11-17 Lomnes Stephen J Contrast agent for combined modality imaging and methods and systems thereof
US20070148194A1 (en) * 2005-11-29 2007-06-28 Amiji Mansoor M Novel nanoemulsion formulations
WO2008102065A1 (fr) * 2007-02-14 2008-08-28 Commissariat A L'energie Atomique Emulsions fluorescentes pour l'imagerie optique
WO2009107859A2 (fr) * 2008-02-29 2009-09-03 Kyoto University Nanopoarticule polymère et agent de contraste pour imagerie optique moléculaire

Also Published As

Publication number Publication date
CA2733994A1 (fr) 2010-02-18
WO2010018460A1 (fr) 2010-02-18
FR2935001A1 (fr) 2010-02-19
CN102170913A (zh) 2011-08-31
EP2331144A1 (fr) 2011-06-15
US20110195029A1 (en) 2011-08-11
JP2011530577A (ja) 2011-12-22

Similar Documents

Publication Publication Date Title
FR2935001B1 (fr) Emulsion fluorescente
BRPI0815828A2 (pt) Formulação de emulsão que impede interação através da interface água-óleo
CY1124094T1 (el) Διαδικασια για την παρασκευη νανογαλακτωματων υδατος-σε-ελαιο και ελαιου-σε-υδωρ
Telley et al. Obstacles on the microtubule reduce the processivity of Kinesin-1 in a minimal in vitro system and in cell extract
Rowland et al. Intracellular FRET-based probes: a review
Yang et al. Versatile application of fluorescent quantum dot labels in super-resolution fluorescence microscopy
ECSP099524A (es) Mousse
Arnspang et al. Multi-color single particle tracking with quantum dots
AR050946A1 (es) Composiciones para el tratamiento de la ropa.
BR112012026706A2 (pt) agregação de informação de item de mídia marcado
CL2010000720A1 (es) Método para la evaluar la respuesta a la inhibición de her en una muestra de paciente, que comprende detectar la proteina marcadora egf (div.sol.no. 1240-06).
Itano et al. Super-resolution imaging of C-type lectin and influenza hemagglutinin nanodomains on plasma membranes using blink microscopy
AR065334A1 (es) Composiciones para bebidas comprendiendo polilisina y por lo menos un acido debil
CL2008001808A1 (es) Emulsion de alta fase interna que comprende elastomero no emulsionante, agua, aceite, emulsionante un estabilizador esterico; composicion que la comprende.
ES2523397B1 (es) Composición de tinta para impresión por inyección
ATE434944T1 (de) Farbstoff-emulsion und emulgatorzusammensetzung sowie deren verwendung
Pinto et al. Development and characterization of repellent formulations based on nanostructured hydrogels
ATE447328T1 (de) Festes produkt mit öltröpfchen
Itano et al. DC-SIGN and influenza hemagglutinin dynamics in plasma membrane microdomains are markedly different
Gorshkov et al. Fluorescent quantum dots enable SARS-CoV-2 antiviral drug discovery and development
Bujak et al. Fast leaps between millisecond confinements govern Ase1 diffusion along microtubules
VanDelinder et al. Photodamage and the importance of photoprotection in biomolecular-powered device applications
Pate et al. Effects of topical alpha-substituted anandamides on intraocular pressure in normotensive rabbits
CY1112023T1 (el) Φαρμακοτεχνικη μορφη νιτροοξυπαραγωγων των nsaids
Mazouchi et al. Sub-diffusion decays in fluorescence correlation spectroscopy: dye photophysics or protein dynamics?

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 8

PLFP Fee payment

Year of fee payment: 9

ST Notification of lapse

Effective date: 20180430